396 related articles for article (PubMed ID: 16827748)
1. Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature.
Hoek KS; Schlegel NC; Brafford P; Sucker A; Ugurel S; Kumar R; Weber BL; Nathanson KL; Phillips DJ; Herlyn M; Schadendorf D; Dummer R
Pigment Cell Res; 2006 Aug; 19(4):290-302. PubMed ID: 16827748
[TBL] [Abstract][Full Text] [Related]
2. Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas.
Reifenberger J; Knobbe CB; Sterzinger AA; Blaschke B; Schulte KW; Ruzicka T; Reifenberger G
Int J Cancer; 2004 Apr; 109(3):377-84. PubMed ID: 14961576
[TBL] [Abstract][Full Text] [Related]
3. Assessment of V600E mutation of BRAF gene and rate of cell proliferation using fine-needle aspirates from metastatic melanomas.
Sviatoha V; Tani E; Ghaderi M; Kleina R; Skoog L
Anticancer Res; 2010 Sep; 30(9):3267-72. PubMed ID: 20944096
[TBL] [Abstract][Full Text] [Related]
4. BRAF mutations in metastatic melanoma: a possible association with clinical outcome.
Kumar R; Angelini S; Czene K; Sauroja I; Hahka-Kemppinen M; Pyrhönen S; Hemminki K
Clin Cancer Res; 2003 Aug; 9(9):3362-8. PubMed ID: 12960123
[TBL] [Abstract][Full Text] [Related]
5. Marked genetic differences between BRAF and NRAS mutated primary melanomas as revealed by array comparative genomic hybridization.
Lázár V; Ecsedi S; Vízkeleti L; Rákosy Z; Boross G; Szappanos B; Bégány A; Emri G; Adány R; Balázs M
Melanoma Res; 2012 Jun; 22(3):202-14. PubMed ID: 22456166
[TBL] [Abstract][Full Text] [Related]
6. NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression.
Omholt K; Platz A; Kanter L; Ringborg U; Hansson J
Clin Cancer Res; 2003 Dec; 9(17):6483-8. PubMed ID: 14695152
[TBL] [Abstract][Full Text] [Related]
7. BRAF and NRAS mutations are uncommon in melanomas arising in diverse internal organs.
Wong CW; Fan YS; Chan TL; Chan AS; Ho LC; Ma TK; Yuen ST; Leung SY;
J Clin Pathol; 2005 Jun; 58(6):640-4. PubMed ID: 15917418
[TBL] [Abstract][Full Text] [Related]
8. Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis.
Willmore-Payne C; Holden JA; Tripp S; Layfield LJ
Hum Pathol; 2005 May; 36(5):486-93. PubMed ID: 15948115
[TBL] [Abstract][Full Text] [Related]
9. Regulation of NR4A nuclear receptor expression by oncogenic BRAF in melanoma cells.
Smith AG; Lim W; Pearen M; Muscat GE; Sturm RA
Pigment Cell Melanoma Res; 2011 Jun; 24(3):551-63. PubMed ID: 21362156
[TBL] [Abstract][Full Text] [Related]
10. Gene expression profiling-based identification of molecular subtypes in stage IV melanomas with different clinical outcome.
Jönsson G; Busch C; Knappskog S; Geisler J; Miletic H; Ringnér M; Lillehaug JR; Borg A; Lønning PE
Clin Cancer Res; 2010 Jul; 16(13):3356-67. PubMed ID: 20460471
[TBL] [Abstract][Full Text] [Related]
11. Human melanoma cells expressing V600E B-RAF are susceptible to IGF1R targeting by small interfering RNAs.
Yeh AH; Bohula EA; Macaulay VM
Oncogene; 2006 Oct; 25(50):6574-81. PubMed ID: 16715137
[TBL] [Abstract][Full Text] [Related]
12. Low prevalence of RAS-RAF-activating mutations in Spitz melanocytic nevi compared with other melanocytic lesions.
Indsto JO; Kumar S; Wang L; Crotty KA; Arbuckle SM; Mann GJ
J Cutan Pathol; 2007 Jun; 34(6):448-55. PubMed ID: 17518771
[TBL] [Abstract][Full Text] [Related]
13. Microarray expression profiling in melanoma reveals a BRAF mutation signature.
Pavey S; Johansson P; Packer L; Taylor J; Stark M; Pollock PM; Walker GJ; Boyle GM; Harper U; Cozzi SJ; Hansen K; Yudt L; Schmidt C; Hersey P; Ellem KA; O'Rourke MG; Parsons PG; Meltzer P; Ringnér M; Hayward NK
Oncogene; 2004 May; 23(23):4060-7. PubMed ID: 15048078
[TBL] [Abstract][Full Text] [Related]
14. A proliferative melanoma cell phenotype is responsive to RAF/MEK inhibition independent of BRAF mutation status.
Zipser MC; Eichhoff OM; Widmer DS; Schlegel NC; Schoenewolf NL; Stuart D; Liu W; Gardner H; Smith PD; Nuciforo P; Dummer R; Hoek KS
Pigment Cell Melanoma Res; 2011 Apr; 24(2):326-33. PubMed ID: 21176117
[TBL] [Abstract][Full Text] [Related]
15. KIT pathway alterations in mucosal melanomas of the vulva and other sites.
Omholt K; Grafström E; Kanter-Lewensohn L; Hansson J; Ragnarsson-Olding BK
Clin Cancer Res; 2011 Jun; 17(12):3933-42. PubMed ID: 21680547
[TBL] [Abstract][Full Text] [Related]
16. Targeting BRAF in melanoma: biological and clinical challenges.
Mandalà M; Voit C
Crit Rev Oncol Hematol; 2013 Sep; 87(3):239-55. PubMed ID: 23415641
[TBL] [Abstract][Full Text] [Related]
17. Constitutive activation of Wnt/beta-catenin signaling pathway in migration-active melanoma cells: role of LEF-1 in melanoma with increased metastatic potential.
Murakami T; Toda S; Fujimoto M; Ohtsuki M; Byers HR; Etoh T; Nakagawa H
Biochem Biophys Res Commun; 2001 Oct; 288(1):8-15. PubMed ID: 11594745
[TBL] [Abstract][Full Text] [Related]
18. Constitutive activation of the mitogen-activated protein kinase signaling pathway in acral melanomas.
Takata M; Goto Y; Ichii N; Yamaura M; Murata H; Koga H; Fujimoto A; Saida T
J Invest Dermatol; 2005 Aug; 125(2):318-22. PubMed ID: 16098043
[TBL] [Abstract][Full Text] [Related]
19. Three novel human sporadic melanoma cell lines: signaling pathways controlled by MC1R, BRAF and β-catenins.
Zanna P; Maida I; Grieco C; Guida S; Turpin Sevilla MC; De Summa S; Tommasi S; Vena GA; Filotico R; Guida G
J Biol Regul Homeost Agents; 2013; 27(1):131-41. PubMed ID: 23489693
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical analysis of BRAF(V600E) expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions.
Busam KJ; Hedvat C; Pulitzer M; von Deimling A; Jungbluth AA
Am J Surg Pathol; 2013 Mar; 37(3):413-20. PubMed ID: 23211290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
